Irinotecan
ایرینوتکان
🎗️ Antineoplastic And Immunomodulating AgentsTopoisomerase I inhibitor
Market / country: 🇺🇸 USA
Camptosar (US)
🧮 Dose calculator
Colorectal cancer · Regimen source: FDA Irinotecan · 2.1, Table 1
- • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Irinotecan · 2.1
- • Single-agent weekly is also 125 mg/m² (days 1, 8, 15, 22 every 6 weeks). UGT1A1*28 homozygous: reduce by one dose level. FDA Irinotecan · 2.2, Table 3FDA Irinotecan · 2.3
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to irinotecan or excipients. FDA Irinotecan · 4
Warnings
- • Boxed warning: early (cholinergic — atropine) and late life-threatening diarrhoea (prompt loperamide); severe myelosuppression. FDA Irinotecan · Boxed Warning
- • Higher neutropenia risk with reduced UGT1A1 activity; hypersensitivity; renal failure; pulmonary toxicity; embryo-fetal toxicity. FDA Irinotecan · 5
Formulations
- 20 mg/mL (40 mg/2 mL, 100 mg/5 mL) — injection 🇺🇸 USA FDA Irinotecan · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Irinotecan · 8.1
“Risk Summary Based on findings from animal studies and its mechanism of action, Irinotecan Hydrochloride Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] .”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Irinotecan · 8.2
“Because of the potential for serious adverse reactions from Irinotecan Hydrochloride Injection in the breastfed child, advise lactating women not to breastfeed during treatment with Irinotecan Hydrochloride Injection and for 7 days after the final dose.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Irinotecan · 8.4
“The effectiveness of irinotecan in pediatric patients has not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Irinotecan · 8.5
“Patients greater than 65 years of age should be closely monitored because of a greater risk of early and late diarrhea in this population [see Clinical Pharmacology (12.3) and Adverse Reactions (6.1) ] .”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Irinotecan · 8.3
“Contraception Irinotecan Hydrochloride Injection can cause fetal harm when administered to a pregnant woman.”
🔗 Reference links
- FDA (approval record)ANDA078589
- DailyMed (FDA label)FDA Irinotecan
- MedlinePlus (NIH)Irinotecan Injection
- WHO ATC/DDDL01CE02
- Darooyab (Iran)Irinotecan
🇮🇷 Registered in Iran Darooyab · G-1018/Irinotecan
Dosage forms with Iranian generic codes, per Darooyab.
- 02088 · IRINOTECAN HCL 100MG/5ML POWDER VIAL · ویال ایرینوتکان هیدروکلراید ۱۰۰ میلیگرم / ۵ میلیلیتر
- 02090 · IRINOTECAN HCL 100MG/5ML SOLUTION FOR INFUSION · محلول انفوزیون ایرینوتکان هیدروکلراید ۱۰۰ میلیگرم / ۵ میلیلیتر
- 21460 · IRINOTECAN HCL 300MG/15ML SOLUTION FOR INFUSION · محلول انفوزیون ایرینوتکان هیدروکلراید ۳۰۰ میلیگرم / ۱۵ میلیلیتر
- 01900 · IRINOTECAN HCL 40MG/2ML POWDER VIAL · ویال ایرینوتکان هیدروکلراید ۴۰ میلیگرم / ۲ میلیلیتر
- 02089 · IRINOTECAN HCL 40MG/2ML SOLUTION FOR INFUSION · محلول انفوزیون ایرینوتکان هیدروکلراید ۴۰ میلیگرم / ۲ میلیلیتر
- 18556 · IRINOTECAN 300MG/15ML VIAL · ویال ایرینوتکان ۳۰۰ میلیگرم / ۱۵ میلیلیتر
- 20298 · IRINOTECAN HYDROCHLORIDE INJECTION, POWDER, FOR SOLUTION INTRAVENOUS 40 mg · پودر تزریقی ایرینوتکان هیدروکلراید ۴۰ میلیگرم
- 20299 · IRINOTECAN HYDROCHLORIDE INJECTION, POWDER, FOR SOLUTION INTRAVENOUS 100 mg · پودر تزریقی ایرینوتکان هیدروکلراید ۱۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Irinotecan · 3FDA Irinotecan · 2.1, Table 1FDA Irinotecan · 2.1FDA Irinotecan · 2.2, Table 3FDA Irinotecan · 2.3FDA Irinotecan · 2.2FDA Irinotecan · 4FDA Irinotecan · Boxed WarningFDA Irinotecan · 5FDA Irinotecan · SPL approval / marketing categoryFDA Irinotecan · 8.1FDA Irinotecan · 8.2FDA Irinotecan · 8.4FDA Irinotecan · 8.5FDA Irinotecan · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1018/Irinotecan
- Clinical review⚠ Unverified